Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].

Enar R.

Turk Kardiyol Dern Ars. 2013 Mar;41(2):166-71. doi: 10.5543/tkda.2013.42716. Review. Turkish.

2.

Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.

Clemmensen P, Dridi NP, Holmvang L.

Cardiovasc Drugs Ther. 2013 Jun;27(3):239-45. doi: 10.1007/s10557-013-6444-2. Review.

PMID:
23380983
4.

Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.

Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A.

Thromb Res. 2013 Jul;132(1):e36-41. doi: 10.1016/j.thromres.2013.05.029. Epub 2013 Jun 19.

PMID:
23791395
5.

Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.

Serebruany VL, DiNicolantonio JJ.

Thromb Haemost. 2013 Jul;110(1):5-10. doi: 10.1160/TH13-02-0142. Epub 2013 Jun 7.

PMID:
23743577
6.

[Myocardial infarction: Role of new antiplatelet agents].

Silvain J, Bellemain A, Ecollan P, Montalescot G, Collet JP.

Presse Med. 2011 Jun;40(6):615-24. doi: 10.1016/j.lpm.2011.03.002. Epub 2011 Apr 20. Review. French.

PMID:
21511430
7.

New antiplatelet agents in the treatment of acute coronary syndromes.

Sabouret P, Taiel-Sartral M.

Arch Cardiovasc Dis. 2014 Mar;107(3):178-87. doi: 10.1016/j.acvd.2014.01.009. Epub 2014 Mar 11. Review.

8.

Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).

Alexopoulos D, Goudevenos JA, Xanthopoulou I, Deftereos S, Sitafidis G, Kanakakis I, Hamilos M, Parissis H, Ntalas IV, Angelidis C, Petousis S, Vavuranakis M, Hahalis G, Stefanadis C; GRAPE Investigators.

Int J Cardiol. 2013 Oct 15;168(6):5329-35. doi: 10.1016/j.ijcard.2013.08.007. Epub 2013 Aug 15.

PMID:
23978364
9.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Kom├│csi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
10.

Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.

Bavishi C, Panwar S, Messerli FH, Bangalore S.

Am J Cardiol. 2015 Sep 1;116(5):809-17. doi: 10.1016/j.amjcard.2015.05.058. Epub 2015 Jun 4. Review.

PMID:
26119655
11.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.

12.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

13.

Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Capranzano P, Mehran R, Tamburino C, Stone GW, Dangas G.

Hosp Pract (1995). 2010 Nov;38(4):38-43. doi: 10.3810/hp.2010.11.338.

PMID:
21068525
14.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.

15.

Antiplatelet options for secondary prevention in acute coronary syndromes.

Silvain J, Cayla G, O'Connor SA, Collet JP, Montalescot G.

Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1403-15. doi: 10.1586/erc.11.139. Review.

PMID:
22059790
16.

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee.

Am Heart J. 2010 Jul;160(1):16-22.e1. doi: 10.1016/j.ahj.2010.04.022.

PMID:
20598967
17.

Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.

Tang XF, Fan JY, Meng J, Jin C, Yuan JQ, Yang YJ.

Atherosclerosis. 2014 Apr;233(2):568-78. doi: 10.1016/j.atherosclerosis.2014.01.017. Epub 2014 Jan 21. Review.

PMID:
24534451
18.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
19.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
20.

Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.

Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q, Bode C, Moser M.

Thromb Haemost. 2014 Feb;111(2):266-72. doi: 10.1160/TH13-06-0508. Epub 2013 Oct 31.

PMID:
24172891

Supplemental Content

Support Center